Good prognosis after imatinib mesylate treatment has been reported if cytogenetic clonal evolution (CE) is the only criterion of accelerated phase (AP) chronic myelogenous leukemia (CML). To evaluate the impact of CE upon imatinib treatment in post-transplant settings, responses and toxicities in the relapsed AP-CE were analyzed in comparison with those in the relapsed chronic phase (CP). Both CP (n ¼ 7) and AP-CE patients (n ¼ 6) received imatinib mesylate in an oral dose of 400 mg/day. Complete cytogenetic responses were obtained in six patients of each group, CP (86%) and AC-CE (100%), while molecular remission was seen in 43 and 50%, respectively. Granulocytopenia or thrombocytopenia of grade III or more occurred in four (57%) and two (33%) patients with CP and AP-CE, respectively. Nonhematological adverse events were mild and tolerable in both groups and only one (7%) of the 13 patients experienced recurrent graft-versus-host disease after imatinib treatment. Although this is a relatively small group of patients, we suggest that imatinib mesylate should be considered as a front-line treatment for relapsed CML as it showed the high response rate and low toxicity. We also suggest that CE alone is not an important factor in the induction of cytogenetic and molecular remissions in post-transplant relapse.
Good prognosis after imatinib mesylate treatment has been reported if cytogenetic clonal evolution (CE) is the only criterion of accelerated phase (AP) chronic myelogenous leukemia (CML). To evaluate the impact of CE upon imatinib treatment in post-transplant settings, responses and toxicities in the relapsed AP-CE were analyzed in comparison with those in the relapsed chronic phase (CP). Both CP (n ¼ 7) and AP-CE patients (n ¼ 6) received imatinib mesylate in an oral dose of 400 mg/day. Complete cytogenetic responses were obtained in six patients of each group, CP (86%) and AC-CE (100%), while molecular remission was seen in 43 and 50%, respectively. Granulocytopenia or thrombocytopenia of grade III or more occurred in four (57%) and two (33%) patients with CP and AP-CE, respectively. Nonhematological adverse events were mild and tolerable in both groups and only one (7%) of the 13 patients experienced recurrent graft-versus-host disease after imatinib treatment. Although this is a relatively small group of patients, we suggest that imatinib mesylate should be considered as a front-line treatment for relapsed CML as it showed the high response rate and low toxicity. We also suggest that CE alone is not an important factor in the induction of cytogenetic and molecular remissions in post-transplant relapse. Allogeneic stem cell transplantation (SCT) is the only curative treatment for chronic myelogenous leukemia (CML), and 40-80% of these patients remain disease free for more than 5 years after SCT.
1 CML recurrence, which occurs in about 20-30% of patients transplanted in the first chronic phase (CP) who receive non-T-cell-depleted marrow, 2 remains as a major cause of treatment failure. Donor lymphocyte infusion (DLI) has become the treatment of choice for relapsed CML and results in complete remission in up to 75% and durable remission with a rate of almost 90% at 2-3 years. However, it has been associated with fatal marrow aplasia and severe graft-versus-host disease (GVHD) and it relies upon the availability of the original donor. [3] [4] [5] Imatinib mesylate is a potent and selective inhibitor of BCR-ABL tyrosine kinase, the product of the chimeric gene produced by the Philadelphia chromosome (Ph). 6, 7 Clinical studies have demonstrated that durable responses are observed in CP patients, although most responding advanced patients relapse despite continued treatment. [8] [9] [10] [11] Thus far, only a limited number of relapsed patients after SCT have been treated with imatinib mesylate, and it induced complete cytogenetic response (CCR) in patients failing DLI, and even induced molecular remission (MR) in some patients. [12] [13] [14] [15] The accelerated phase (AP) is an intermediate stage, in which patients show signs of disease progression such as increasing constitutional symptoms, progressive splenomegaly, progressive leukocytosis or thromocytosis, and clonal evolution. However, whether clonal evolution (CE) in the absence of other features of AP should be considered as AP remains controversial, because it does not adversely affect the outcome after interferon plus low-dose cytarabine treatment or SCT. [16] [17] [18] We undertook this study to evaluate the impact of CE upon treatment with 400 mg/day of imatinib in post transplant settings by comparing the results of AP with CE alone (AP-CE) and those of CP after transplantation.
Patients and methods

Patients
Adults with Ph or BCR-ABL-positive CML that had relapsed after transplantation were eligible to participate in this study. Eligibility criteria included having disease in the CP with molecular, cytogenetic, or hematological evidence of relapse or disease with CE as the sole criterion of AP, without the other features described by Kantarjian et al. 19 CE included the duplication of Ph chromosome as well as the acquisition of new chromosomal abnormalities, which had not existed before transplantation. Written informed consent was received from each patient prior to enrollment in this study.
Treatment with imatinib mesylate
Imatinib mesylate was started at oral dose of 400 mg daily for all enrolled patients and doses were adjusted according to the previously published guidelines. 8, 14 The treatment was continued until the disease was considered unresponsive (no hematological response after at least 4 weeks or no cytogenetic response after at least 6 months of treatment) to imatinib mesylate, death, a change to another treatment (eg, DLI), or the appearance of unacceptable adverse events that did not respond to dose modification. 
Response analysis
Cytogenetics
Conventional cytogenetics were performed in a standard manner by Giemsa banding with a minimum of 20 metaphases examined each time. FISH were performed, as previously described 20 and at least 500 nuclei were counted for hybridization signals using an epifluorescence microscope fitted with triple-pass filters (Nikon E800, Nikon, Japan).
PCR assays
RT-PCR and Q-RT-PCR were performed as previously described. 21, 22 To be brief, total RNA was extracted using an RNAqueous Kit (Ambion, Austin, TX, USA) and reverse transcription was performed using 1 mg RNA. The two-step nested procedure was used for the nested RT-PCR amplification (sensitivity, 10
À6
). The plasmid standard titrations with the defined copy numbers for BCR-ABL and reference ABL were analyzed simultaneously with the patient samples. Using one set of primers for each type of BCR-ABL transcript, ABL, and TaqMan probes, Q-RT-PCR was performed in triplicate reactions using the iCycler software 2.1 (Bio-Rad, Hercules, CA, USA) in the standard conditions (951C for 10 min, 50 cycles at 951C for 15 s, and 601C for 1 min). The 50 ml PCR reaction mix contained 5 ml of 1 Â PCR buffer, 4.5 mM MgCl 2 , 0.2 mM dNTP, 0.2 mM primer, 140 nM TaqMan probe, 1.25 U AmpliTaq Gold DNA polymerase, and 4 ml target cDNA. The quantity of the BCR-ABL transcript was normalized for ABL expression (sensitivity, 10
À5
).
Chimerism analysis
Chimerism analysis using multiplex short tandem repeat was performed with the AmpFlSTR Identifier PCR Amplification Kit (PE Applied Biosystems, Foster City, CA, USA) and fragments were analyzed on an ABI Prism 310 Genetic Analyzer (PE Applied Biosystems), as previously described. 23 
Statistical analysis
The end points were calculated on 31 January 2003, which was the date of the last follow-up. Fisher's exact test and the Mann-Whitney test were employed to compare the appropriate groups. All quoted P-values are two-sided and statistical significance was accepted at Po0.05.
Results
Patients
A total of 13 patients with a median age of 32, in whom CML had relapsed at a median of 18.8 months after SCT, Standardised BCR-ABL transcripts were enrolled. The duration of imatinib mesylate treatment was a median 351 days (range, 15-552 days). Before imatinib mesylate treatment, immunomodulatory treatment such as immunosuppressant withdrawal, DLI, or interferon was given to all patients except one, but 10 patients were refractory (defined as no hematological response at 3 months or no cytogenetic response at 6 months after treatment) to these treatment. The disease phase at the initiation of imatinib mesylate treatment was CP in seven patients and AP-CE in six patients. The median time to relapse or start of imatinib mesylate after transplantation was shorter in AP-CE (10.1 and 18.4 months, respectively) than in CP (28.2 and 39.0 months, respectively). Other characteristics such as sex, age, transplant type, and previous salvage treatment and its refractoriness were not different between these two groups ( Table 1) . Pretreatment karyotypes in six AP-CE patients are shown Table 2 .
Treatment responses
CCR was observed in 12 (82%) of the 13 patients. Among the seven CP patients, six (86%) experienced CCR and the cumulative incidences after 3, 6, and 9 months on imatinib mesylate treatment were 57, 71, and 86%, respectively (Table 3) . In contrast, all six patients in AP-CE group achieved CCR within 3 months of treatment. CCR persisted for 52-515 days in all responding patients. MR occurred in three (43%) of the CP group, each patient in 9, 12, and 15 months and in three (50%) of the AP-CE group, each in 3, 6, and 12 months. These responses persisted for 85-259 days in all except one (case 4), in whom BCR-ABL transcripts reappeared after 84 days of MR. Of the 10 patients who had been refractory to immunomodulatory treatment, nine achieved CCR, but MR was achieved in only three patients (30%). On the contrary, all three remaining patients who had not been refractory achieved MR.
Kinetics of minimal residual disease
Quantitative monitoring by Q-RT-PCR showed that the rapid decline of normalized BCR-ABL transcripts occurred during the early phase of imatinib mesylate treatment in all patients except one (case 1), in whom Q-RT-PCR results did not decrease even after the continuation of imatinib mesylate for 12 months. In three patients (cases 2, 11, and 12), normalized BCR-ABL transcripts either plateaued or slowly increased after 6 months of initial decline. These four patients had been refractory to previous interferon (case 1) or DLI plus interferon (cases 2, 11, and 12).
Toxicities and GVHD
Granulocytopenia or thrombocytopenia of grade III or more occurred in four patients (57%) in CP and two patients (33%) in AP-CE. Nonhematological adverse events due to imatinib were edema (n ¼ 8), myalgia (n ¼ 4), arthralgia (n ¼ 2), and diarrhea (n ¼ 1), but all were mild (gradepII) and tolerable in both groups. Only one patient (case 7) experienced recurrent GVHD; extensive GVHD after immunosuppressant withdrawal had been tolerable but recurred 15 days after imatinib mesylate treatment. Although the drug was promptly discontinued, the patient died of severe hepatic GVHD. Imatinib was also discontinued in another patient (case 8) because of preexisting hepatic GHVD that had been poorly controlled before the initiation of imatinib mesylate.
Discussion
The present study shows the high rate of cytogenetic responses achieved after imatinib treatment at a dose of 400 mg/day both in patients with relapsed AP-CE and relapsed CP. These findings suggest that the acquisition of CE after transplantation in the absence of any other signs of disease acceleration does not adversely affect the Table 1 Characteristics of patients according to disease phase induction of response by imatinib mesylate. This is similar to the cases in nontransplant settings; CCR was observed in 16-31% of AP patients with accelerated features other than CE alone, whereas the corresponding figure in patients with CE alone was 60%. 8, 24 However, recent data showed that although CE was not an important factor for achieving major or CCR with imatinib mesylate treatment, it was an independent poor prognostic factor for survival in CP CML. 25 As additional chromosomal aberrations are regarded to be one of the possible causes of imatinib resistance, 26 it could influence the responses to imatinib mesylate. In this study, however, all patients with AP-CE remained in CCR and were alive for more than 1 year. Of course, CE after transplantation, which occurs by random, sometimes transient, chromosomal changes, [27] [28] [29] differs from the evolution seen in conventionally treated patients. These changes are presumably due to conditioning prior to transplantation and it is not generally believed to be of clinical significance, which was also revealed in this study by examining the induction of response and survival in imatinib mesylate treatment for relapsed CML.
The high rate of MR observed in the present study vs that in nontransplant settings was another interesting point. This finding indicates that, in post translant relapse, the graft-versus-leukemia effect might work to eradicate the BCR-ABL-expressing leukemic clone in addition to the direct antileukemic activity of imatinib mesylate, which is supported by the observation that one patient in the present study achieved CCR after the re-emergence of severe GVHD induced by just 15 days of imatinib mesylate treatment. As most patients did not experience GVHD recurrence, it is unlikely that immunological mechanisms contributed significantly to this early response. However, there remains a possibility that the graft-versus-leukemia effect might have been separated from GVHD and an immunological antileukemic effect could not be ruled out.
The kinetic study of MRD after imatinib mesylate treatment in this study showed that BCR-ABL transcripts [3] / 46,Y,der(X)t(X;11)(q22;q12),del(2)(p23),add(6)(p25),der (11) a Philadelphia-negative, BCR-ABL-positive CML. did not decrease further even after the continuation in some patients, especially having refractoriness to preceding immunomodulatory treatment. Thus, therapeutic strategies for these patients should be established to eradicate residual BCR-ABL-positive clones. One possible approach is a dose escalation of imatinib; high-dose imatinib led to more favorable outcomes compared to standard-dose imatinib. 8, 30 In addition, dose escalation was reported to be beneficial to overcoming resistance to standard-dose treatment. 31 However, it is unknown whether dose-dependent responsiveness exist in patients with CE after transplantation. Another possible candidate, other than dose escalation, could be combinations of imatinib mesylate with DLI, low-dose cytarabine, or interferon.
The relative safety of imatinib mesylate in post transplant settings was demonstrated in our study, which concurs with the findings of other investigators. [12] [13] [14] [15] Hematological and nonhematological adverse events were mild or reversible after dose reductions. GVHD after imatinib treatment was only 8% in this study. Literature reviews showed that severe GVHD was observed in a relatively smaller portion of relapsed patients compared to those observed after DLI. 5, [12] [13] [14] [15] 32, 33 It seems likely that the re-emergence of GVHD is not wholly associated with the response to imatinib mesylate.
Although this study was conducted on a small group of patients, we suggest that imatinib mesylate should be used as a front-line treatment for relapsed CML because of the high response rate and minimal toxicity, as reported by many investigators. [12] [13] [14] [15] We also suggest that cytogenetic CE alone does not adversely affect response to imatinib mesylate treatment in post transplant settings.
